Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
If they reach predicted throughput targets in Q3 they will become a profitable company and the sp will go back well above 1p.
The only reason for the massive drop was because a certain investor who's name we cannot mention made it known that he was bailing out. By how much has he reduced his holding since that day ?????? Would he sell up at a massive loss????? Nothing stopping the SP going back above 1p imho.
I think it's Morton buying.
I think it's Morton buying.
Yep I get it but I thought Canaccord had bought in also. Confusing .
I think you're right Graham. Shame. Still we have one big name and it looks like they are buying on the open market.
No read point 11. of the announcement
Another big name joins us.
Wow if that's going to cost 3 million then I'm out
The big issue is that they need to raise cash which will be difficult after bad news.
Iclaprim is an optimized analog of trimethoprim that was discovered by scientists at Roche.[5] Arpida was spun out of Roche in 1998[5][6] and acquired iclaprim from Roche in 2001.[7]:77 Arpida held an IPO on the Swiss stock exchange in 2005.[8]
Arpida ran two Phase III clinical trials for complicated skin and skin structure infections, called ASSIST 1 and 2, that were completed by 2008 but as of 2017 had not been published in the medical literature.[2] A new drug application was filed with the FDA bssed on these trials and was rejected due to failure to show non-inferiority and due to safety concerns, especially drug-induced QT prolongation.[2][9] The FDA advisory committee said that the drug "should not be developed further" based on the results presented.[10] A parallel application for marketing approval to the EMA was withdrawn in 2009; in the announcement of the withdrawal, the EMA said that there was insufficient data from clinical studies to justify the dosage proposed by the company and that resistance to the drug had already been seen in the clinical trial data.[11]
Arpida collapsed after the rejection by the FDA and the EMA withdrawal.[6] Arpida and the privately owned Swiss company Evolva began discussing an acquisition of Arpida by Evolva, which would allow Evolva to go public via a reverse merger in September 2009.[12] Arpida sold off iclaprim to Acino Pharma in November 2009,[13] and in December 2009 Arpida and Evolva completed their transaction.[14]
Acino sold the rights to iclaprim, its data and regulatory filings, and manufactured drug to a group called Life Sciences Management Group, Inc. of Bethesda, Maryland, in September 2013 and that company assigned its rights to a company called Nuprim,[7]:F-32 which had been formed by the former CEO, CSO, and US agent of Arpida in 2014.[15] In December 2014 Motif BioSciences Inc. and Nuprim signed an agreement allowing Motif to acquire the iclaprim assets, and the transaction was completed in April 2015.[7]:iv